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Recently, our group has discovered a family suffering
from premature coronary artery disease (CAD) and myo-
cardial infarction (MI). Whole-exome sequencing of
three affected family members revealed that these shared
a mutation in the PDE5A gene encoding the phospho-
diesterase 5A protein. Mutations in proteins involved in
cGMP-signalling have already been shown to play an
important role in premature CAD/MI [1]. Here, we
aimed to characterize the effect of this mutation at the
molecular level.
PDE5A encodes three distinct isoforms, PDE5A1,
PDE5A2, and PDE5A3, all of which cleave cGMP, a sec-
ond messenger that plays an important role in e.g.
smooth muscle relaxation and thrombocyte passivation.
The particular mutation is located in the first intron of
PDE5A1 and PDE5A3, which is known to be an alterna-
tive promoter site [2], and in the first exon of PDE5A2,
generating a premature stop codon. Stable isotope label-
ing by amino acids in cell culture (SILAC) analysis in
HeLa S3 nucleus cell lysates revealed allele-specific bind-
ing of the transcription factor ZFX to the major allele. In
line, reporter gene analysis of the first intron of PDE5A1
and PDE5A3 by luciferase assay pointed to significantly
different promoter activities of the investigated alleles in
HEK293 cells with 40% increased activity of the mutated
allele. Furthermore, overexpression experiments of the
mutated construct in HEK293E cells did not show a loss
of transcript as supposed by the premature stop codon
but hinted towards the expression of an N-terminal trun-
cated PDE5A2 isoform.
We demonstrated an increased promoter activity of
the mutated PDE5A allele which might lead to increased
expression of PDE5A isoforms. This differential promo-
tor activity could be mediated by allele-specific binding
of the transcription factor ZFX, which is part of current
studies. As the N-terminus of PDE5A, i.e. the GAF-
domain, act as an important regulator of enzymatic activ-
ity [3], we hypothesize that the truncated PDE5A2 isoform
might be more active. Overall, our results point towards a
gain of function mutation in PDE5A associated with pre-
mature CAD and MI.
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